SCHEMBL3608848

SCHEMBL3608848

Cc1cccc(-n2ncc3c(=O)n(-c4ccccc4)cnc32)c1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 6/20 0.55
KDM4E B2RXH2 5/20 0.55
NPC1 O15118 5/20 0.55
HSD17B10 Q99714 3/20 0.55
HTT P42858 3/20 0.55
NPSR1 Q6W5P4 2/20 0.55
BLM P54132 1/20 0.55
MAPT P10636 5/20 0.54
TP53 P04637 4/20 0.53
GRM1 Q13255 1/20 0.53
TSHR P16473 3/20 0.53
CYP1A2 P05177 1/20 0.53
SMN1; SMN2 Q16637 6/20 0.52
LMNA P02545 3/20 0.52
ALDH1A1 P00352 3/20 0.52
HPGD P15428 2/20 0.52
MEN1 O00255 1/20 0.52
KMT2A Q03164 1/20 0.52
THRB P10828 1/20 0.51
DPP4 P27487 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3612236 0.87 RAB9A (0.61) RAB9AKDM4EHSD17B10HTTMAPT
SCHEMBL3616124 0.86 SMN1; SMN2 (0.65) RAB9AKDM4EHSD17B10HTTNPSR1
SCHEMBL3612259 0.81 FSCN1 (0.54) RAB9AKDM4EHSD17B10HTTNPSR1
SCHEMBL3613365 0.81 SMN1; SMN2 (0.68) RAB9AKDM4EHSD17B10HTTNPSR1
SCHEMBL3612174 0.81 RAB9A (0.59) RAB9AKDM4EHSD17B10HTTTSHR
SCHEMBL3615612 0.80 LMNA (0.60) RAB9AKDM4ENPC1HSD17B10HTT
SCHEMBL3602075 0.80 POLB (0.62) RAB9AKDM4ENPC1HSD17B10HTT
SCHEMBL31759280 0.77 MEN1 (0.60) RAB9AKDM4ENPC1TSHRSMN1; SMN2
SCHEMBL3614046 0.77 LMNA (0.55) RAB9AKDM4EHSD17B10NPSR1TSHR
SCHEMBL3608846 0.77 TP53 (0.56) RAB9AKDM4ENPC1HSD17B10HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100137340-A1 FUSED PYRIMIDINONE COMPOUNDS AS MGLUR LIGANDS GLATTHAR RALF 2010-06-03 US disclosed
EP-2132210-A1 FUSED PYRIMIDINONE COMPOUNDS AS MGLUR LIGANDS Novartis AG (CH) 2009-12-16 EP disclosed
WO-2008107418-A1 FUSED PYRIMIDINONE COMPOUNDS AS MGLUR LIGANDS NOVARTIS AG (CH) 2008-09-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100137340-A1 FUSED PYRIMIDINONE COMPOUNDS AS MGLUR LIGANDS GRM1, GRM2, GRM3 RAB9A 1068/4885KDM4E 1514/4885NPC1 787/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.